Skip to content

Alcon

US · ALC #656 by market cap Listed 1970
74.31 -0.19 -0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Surgical is the largest reported line at 54.47% of revenue, across 2 reported segments.
  • Vision Care follows at 45.53%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 8 years

Latest year +4.94% YoY

Margins

Gross margin
55.24%
Operating margin
13.08%
Net margin
9.42%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (43.02%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 7.15B7.51B6.83B8.29B8.72B9.46B9.91B10.40B
Gross profit 3.19B3.66B2.94B4.65B4.75B5.25B5.51B5.75B
Selling & admin expenses 2.80B2.85B2.69B3.08B3.07B3.21B3.25B3.45B
Research & development 587.00M656.00M673.00M842.00M702.00M828.00M876.00M990.00M
Operating profit -248.00M-187.00M-482.00M580.00M672.00M1.04B1.41B1.36B
Pretax profit -300.00M-332.00M-635.00M418.00M463.00M832.00M1.26B1.16B
Tax -73.00M324.00M-104.00M42.00M128.00M-142.00M238.00M180.00M
Net profit -227.00M-656.00M-531.00M376.00M335.00M974.00M1.02B980.00M
Basic EPS 0-1-111222
Diluted EPS -0.46-1.34-1.090.760.681.962.051.98

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 3.40B4.24B4.99B5.39B5.19B5.65B6.31B6.45B
Cash & ST investments 258.00M855.00M1.57B1.58B980.00M1.10B1.83B1.61B
Inventory 1.44B1.51B1.64B1.90B2.11B2.32B2.27B2.39B
Total assets 27.06B27.66B27.60B28.00B29.17B29.61B30.35B31.56B
Total current liabilities 1.89B2.30B2.26B2.47B2.74B2.40B2.28B3.05B
Short-term debt 47.00M306.00M232.00M174.00M168.00M124.00M169.00M649.00M
Long-term debt --3.22B3.95B3.97B4.54B4.68B4.54B4.16B
Total liabilities 4,423,000,000.008,352,000,000.008,778,000,000.008,743,000,000.009,488,000,000.008,990,000,000.008,794,000,000.009,520,000,000.00
Total equity 22.64B19.30B18.82B19.26B19.68B20.62B21.55B22.04B
Retained earnings ----------------

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 1.14B920.00M823.00M1.35B1.22B1.39B2.08B2.27B
Depreciation & amortization 1.62B1.43B1.62B1.22B1.12B1.22B1.23B1.34B
Free cash flow 428.00M244.00M256.00M165.00M472.00M537.00M1.41B1.61B
Dividends paid --00-54.00M-100.00M-116.00M-130.00M-166.00M
Stock buybacks / issuance ----------00-676.00M
Ending cash balance 227.00M822.00M1.56B1.58B980.00M1.09B1.68B1.53B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % -1.48-3.38-2.791.971.724.834.834.50
ROA % -1.15-2.39-1.921.351.173.313.403.17
ROIC % -0.95-2.47-1.862.051.734.324.224.04
5-year avg ROE % -------0.76-0.640.522.113.57
EBIT margin % -3.92-2.92-7.486.496.8510.8014.6113.11
FCF / sales % 5.883.253.751.995.415.6814.2015.46
Current ratio 1.801.842.212.181.902.352.772.12
Quick ratio 1.011.151.441.371.081.341.721.29
Debt / assets 0.5013.7616.2916.0017.3817.3416.9216.61
LT debt / equity 0.3918.1222.6522.3624.9024.3023.0520.84
Interest coverage -2.26-1.94-4.124.484.465.407.546.69
Revenue CAGR (3Y) % --4.410.205.045.1011.436.136.06
Net income CAGR (3Y) % ------------39.3843.02
FCF CAGR (3Y) % ---30.88-29.22-27.2224.6028.01104.3050.47

Revenue breakdown most recent period

Business

Surgical54.47%
Vision Care45.53%

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Alcon discussion 0 comments

Add a comment